Volume 10, Issue 3 (7-2012)                   IJRM 2012, 10(3): 219-222 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghahiri A, Najafian A, Ghasemi M, Najafian A. Comparison study on effectiveness of pentoxifyllin with LD to prevent recurrent endometriosis. IJRM 2012; 10 (3) :219-222
URL: http://ijrm.ir/article-1-283-en.html
Comparison study on effectiveness of pentoxifyllin with LD to prevent recurrent endometriosis
Ataollah Ghahiri1 , Aida Najafian1 , Mojdeh Ghasemi * 2, Alireza Najafian3
1- Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Isfahan, Iran
2- Research Office of Shahid Beheshti Hospital, Isfahan University of Medical Sciences, Isfahan, Iran , md_ghasemi@yahoo.com
3- Research assistant, Isfahan Endocrine and Metabolism Research Center (IEMRC), Isfahan, Iran
Abstract:   (4528 Views)
Background: About 75% of the symptomatic patients who involved with endometriosis have pelvic pain and dysmenorrhea. Pentoxifyllin is one of the drugs that according to its mechanism could be effective for pain relief of endometriosis which has been used for endometriosis treatment recently.
Objective: We conducted a comparative study for detecting the effect of pentoxifylin (as an immonomodelator) in preventing recurrence endometriotic pain with pentoxifylin plus a combined contraceptive pill with low dose estrogen (LD) and also the LD pill alone.
Materials and Methods: This was a comparative clinical trial on 83 patients with the chief complaint (CC) of pain (dysmenorrheal /or pelvic pain) and with the end diagnosis of endometriosis, in an operative laparoscopy. Patients, dividing to 3 groups, were treated with pentoxifylin, pentoxifylin+LD and LD alone for 10 months. The severity of pain (dismenorhea and/or pelvic pain) was detected by visual analogue scale (VAS) before and after the treatment. The severity of endometriosis in the patients was: I in class I and II in class II and III in class III. The groups were matched for the pain. The number of the patients in group 1, 2 and 3 were 28, 28 and 27 respectively.
Results: The pain was reduced in the groups of pentoxifylin+LD (p<0.001) and LD alone (p=0.00). The pain relief was not significant in the group of pentoxifylin alone (p=0.136). After treatment, the severity of pain was not significantly different between the LD group and the LD+penthoxyfillin group, but there was difference between these two groups and the group of penthoxyfillin alone.
Conclusion: This study showed that penthoxyfillin actually could not have any effect on the pain relief of endometriosis. It also made it clear that penthoxyfillin could not increase the efficacy of LD when used with this medication.
Keywords:  Endometriosis, Penthoxyfillin, Combined contraceptive pill (low dose estrogen) (LD)
Full-Text [PDF 191 kb]   (669 Downloads) |   |   Full-Text (HTML)  (298 Views)  
Type of Study: Original Article |
References
1. Sangi-Haghpeykar H, Poindexter AN 3rd. Epidemiology of endometriosis among parous women. Obstet Gynecol 1995; 85: 983-992. [DOI:10.1016/0029-7844(95)00074-2]
2. Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril 2008; 89: 538-545. [DOI:10.1016/j.fertnstert.2007.03.069]
3. Seaman HE, Ballard KD, Wright JT, de Vries CS. Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study. BJOG 2008; 115: 1392-1396. [DOI:10.1111/j.1471-0528.2008.01879.x]
4. Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306: 182-184. [DOI:10.1136/bmj.306.6871.182]
5. Moen MH. Is a long period without childbirth a risk factor for developing endometriosis? Hum Reprod 1991; 6: 1404-1407. [DOI:10.1093/oxfordjournals.humrep.a137278]
6. Parazzini F, La Vecchia C, Franceschi S, Negri E, Cecchetti G. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol 1989; 18: 108-112. [DOI:10.1093/ije/18.1.108]
7. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80: 560-563. [DOI:10.1016/S0015-0282(03)00794-5]
8. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60: 75-79. [DOI:10.1016/S0015-0282(16)56039-7]
9. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001; 4: CD002120.
10. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90: 1583-1588. [DOI:10.1016/j.fertnstert.2007.08.051]
11. Buttram VC Jr. Cyclic use of combination oral contraceptives and the severity of endometriosis. Fertil Steril 1979; 31: 347-348. [DOI:10.1016/S0015-0282(16)43887-2]
12. Strathy JH, Molgaard CA, Coulam CB, Melton LJ 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38: 667-672. [DOI:10.1016/S0015-0282(16)46691-4]
13. Kirshon B, Poindexter AN 3rd. Contraception: a risk factor for endometriosis. Obstet Gynecol 1988; 71: 829-831.
14. Mahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod 1991; 6: 544-549. [DOI:10.1093/oxfordjournals.humrep.a137377]
15. Moen MH. Endometriosis in women at interval sterilization. Acta Obstet Gynecol Scand 1987; 66: 451-454. [DOI:10.3109/00016348709022053]
16. Davis L, Kennedy SS, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; 3: CD001019.
17. Hamle J. Release of tumor necrosis factor-α by human peritoneal macrophages invivo and in vitro. Am J Obstet Gynecol 1989; 161: 1718-1725. [DOI:10.1016/0002-9378(89)90957-5]
18. Steinleitner A, Lambert H, Suarez M, Serpa N, Roy S. Immunomodulation in the treatment of endometriosis-associated subfertility: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model. Fertil Steril 1991; 56: 975-979. [DOI:10.1016/S0015-0282(16)54674-3]
19. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21: 248-256. [DOI:10.1093/humrep/dei290]
20. Balasch J, Creus M, Fábregues F, Carmona F, Martínez-Román S, Manau D, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod 1997; 12: 2046-2050. [DOI:10.1093/humrep/12.9.2046]
21. Alborzi S, Ghotbi S, Parsanezhad ME, Dehbashi S, Alborzi M. Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study. J Min Invas Gynecol 2007; 14: 54-58. [DOI:10.1016/j.jmig.2006.06.024]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb